4D Molecular Therapeutics 4Front-2 试验超额招募，预计入组人数超500；最终随机化预计于2026年第三季度进行

美股速递06-29

4D Molecular Therapeutics 宣布，其4Front-2临床试验已实现超额招募，预计最终入组患者人数将超过500名。这项关键性试验旨在评估其基因疗法在特定适应症中的疗效与安全性。公司预计，最终的随机化分配步骤将于2026年第三季度完成，这标志着试验进程向前迈出了至关重要的一步。试验的顺利推进与积极的招募数据，为后续的数据分析和潜在监管申报奠定了坚实基础。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1109306030?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-29 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109306030","market":"us","top_or_hot":-1,"title":"4D Molecular Therapeutics 4Front-2 试验超额招募，预计入组人数超500；最终随机化预计于2026年第三季度进行","media":"美股速递","content":"<p>4D Molecular Therapeutics 宣布，其4Front-2临床试验已实现超额招募，预计最终入组患者人数将超过500名。这项关键性试验旨在评估其基因疗法在特定适应症中的疗效与安全性。公司预计，最终的随机化分配步骤将于2026年第三季度完成，这标志着试验进程向前迈出了至关重要的一步。试验的顺利推进与积极的招募数据，为后续的数据分析和潜在监管申报奠定了坚实基础。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4D Molecular Therapeutics 4Front-2 试验超额招募，预计入组人数超500；最终随机化预计于2026年第三季度进行</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4D Molecular Therapeutics 4Front-2 试验超额招募，预计入组人数超500；最终随机化预计于2026年第三季度进行\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-29 20:02 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4D Molecular Therapeutics 宣布，其4Front-2临床试验已实现超额招募，预计最终入组患者人数将超过500名。这项关键性试验旨在评估其基因疗法在特定适应症中的疗效与安全性。公司预计，最终的随机化分配步骤将于2026年第三季度完成，这标志着试验进程向前迈出了至关重要的一步。试验的顺利推进与积极的招募数据，为后续的数据分析和潜在监管申报奠定了坚实基础。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FDMT","symbol_name":"4D Molecular Therapeutics","start_time":0,"source_url":"","article_id":"1109306030","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109306030","pubTimestamp":1782734525,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"4D Molecular Therapeutics 宣布，其4Front-2临床试验已实现超额招募，预计最终入组患者人数将超过500名。这项关键性试验旨在评估其基因疗法在特定适应症中的疗效与安全性。公司预计，最终的随机化分配步骤将于2026年第三季度完成，这标志着试验进程向前迈出了至关重要的一步。试验的顺利推进与积极的招募数据，为后续的数据分析和潜在监管申报奠定了坚实基础。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"FDMT":"4D Molecular Therapeutics","BK4139":"生物科技"},"translate_title":"4D Molecular Therapeutics 4Front-2 The trial is over-recruited, and the number of enrollees is expected to exceed 500; Final randomization expected in the third quarter of 2026","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FDMT":1},"content_text":"4D Molecular Therapeutics 宣布，其4Front-2临床试验已实现超额招募，预计最终入组患者人数将超过500名。这项关键性试验旨在评估其基因疗法在特定适应症中的疗效与安全性。公司预计，最终的随机化分配步骤将于2026年第三季度完成，这标志着试验进程向前迈出了至关重要的一步。试验的顺利推进与积极的招募数据，为后续的数据分析和潜在监管申报奠定了坚实基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109306030","isCrawlerRequest":true}